| Description |
1 online resource (329 pages) |
| Series |
Pan Stanford Series on Nanobiotechnology Ser |
|
Pan Stanford series on nanobiotechnology.
|
| Contents |
Cover; Half Title; Title Page; Copyright Page; Dedication; Table of Contents; Preface; 1: NANOTECHNOLOGY APPLICATIONS OF NUCLEIC ACID PROGRAMMABLE PROTEIN ARRAYS; 1.1 Introduction; 1.2 Materials and Methods; 1.2.1 The FLEXGene repository; 1.2.2 Nucleic Acid-Programmable Protein Array (NAPPA); 1.2.3 Protein-protein interactions; 1.3 Results; 1.3.1 Atomic force microscopy (AFM); 1.3.2 Nanogravimetry; 1.3.3 Mass spectrometry (MS); 1.3.4 Anodic porous alumina (APA); 1.3.5 Fluorescence via DNASER and bioinformatics; 1.3.6 Transcription translation kit; 1.4 Discussion; 1.5 Conclusions |
|
AcknowledgmentsReferences; 2: BIOINFORMATICS AND FLUORESCENCE DNASER FOR NAPPA STUDIES ON CELL TRANSFORMATION AND CELL CYCLE; 2.1 Introduction; 2.2 Materials and Methods; 2.2.1 The experimental layout; 2.2.2 Procedure of NAPPA expression and DNASER analysis; 2.3 Results; 2.3.1 NAPPA DNASER imaging; 2.3.2 NAPPA-targeted prediction of gene interactions relevant to progressing between phases of cell cycle of human T lymphocytes; 2.3.3 NAPPA-targeted prediction of protein interactions relevant to differences between lymphoma and normal T cells; 2.3.4 Planned experimentation; 2.4 Conclusions |
|
AcknowledgmentsReferences; 3: LABEL FREE DETECTION OF NAPPA VIA MASS SPECTROMETRY; 3.1 Introduction; 3.2 Materials and Methods; 3.2.1 The experimental layout; 3.2.2 Fabrication of NAPPA; 3.2.3 NAPPA expression; 3.2.4 Autoflex analysis; 3.3 Results; 3.3.1 Human kinase NAPPA; 3.3.2 NAPPA for MS; 3.3.2.1 Matching algorithm; 3.4 Conclusions; Acknowledgments; References; 4: LABEL FREE NAPPA VIA NANOGRAVIMETRY; 4.1 Introduction; 4.2 Materials and Methods; 4.2.1 QCM-frequency technique; 4.2.2 QCM-D dissipation (quality) factor technique; 4.3 Results; 4.4 Conclusions and Suggestions; Acknowledgments |
|
6.2 Materials and Methods6.2.1 Technical details for NAPPA imaging by AFM; 6.3 Results; 6.3.1 NAPPA investigations with the functionalization of cantilever and the measurement of interaction forces; 6.4 Conclusions and Advancements; Acknowledgments; References; 7: CELL FREE EXPRESSION AND APA FOR NAPPA AND PROTEIN NANOCRYSTALLOGRAPHY; 7.1 Introduction; 7.2 APA and NAPPA Microarray; 7.3 Background of Cell-Free Protein Synthesis; 7.4 APA-Cell Free and Protein Nanocrystallography; 7.5 Materials and Methods; 7.5.1 The PURExpress system and its advantages; 7.5.2 APA template preparation |
| Summary |
This volume introduces in a coherent and comprehensive fashion the Pan Stanford Series on Nanobiobiotechnology by defining and reviewing the major sectors of Nanobiotechnology and Nanobiosciences with respect to the most recent developments. Nanobiotechnology indeed appears capable of yielding a scientific and industrial revolution along the routes correctly foreseen by the numerous programs on Nanotechnology launched over the last decade by numerous Councils and Governments worldwide, beginning in the late 1995 by the Science and Technology Council in Italy and by the President Clinton in USA and ending this year with President Putin in Russian Federation |
| Bibliography |
References5: LABEL-FREE NAPPA: ANODIC POROUS ALUMINA; 5.1 Introduction; 5.2 Materials and Methods; 5.2.1 Experimental details; 5.2.2 Mechanical tests for anodic porous alumina; 5.2.2.1 Grip test; 5.2.2.2 Ball-crush test; 5.2.2.3 APA over glass slides and reversibility test; 5.3 Results; 5.3.1 Electric impedance spectroscopy set up for NAPPA analysis; 5.3.2 Sponge effect and application to existing spotting systems; 5.3.3 AFM analysis of APA samples; 5.4 Conclusions; Acknowledgments; References; 6: LABEL FREE DETECTION OF NAPPA VIA ATOMIC FORCE MICROSCOPY; 6.1 Introduction |
| Notes |
7.5.2.1 APA process |
|
Dr. Joshua LaBaer is one of the nation's foremost investigators in the rapidly expanding field of personalized medicine. Formerly director of the Harvard Institute of Proteomics (HIP), he was recently recruited to ASU's Biodesign Institute as the first Piper Chair in Personalized Medicine. Dr. LaBaer's efforts involve leveraging the Center's formidable resources for the discovery and validation of biomarkers-unique molecular fingerprints of disease-which can provide early warning for those at risk of major illnesses, including cancer and diabetes. This work is carried out in conjunction with the Partnership for Personalized Medicine, a multi-institution effort that includes the Translational Genomics Research Institute (TGen) in Phoenix and the Fred Hutchinson Cancer Research Institute in Seattle. Dr. LaBaer completed his internship and residency at the Brigham and Women's Hospital and a clinical fellowship in Oncology at the Dana-Farber Cancer Institute, both in Boston. He is a board certified physician in Internal Medicine and Medical Oncology and was an Instructor and Clinical Fellow in Medicine at Harvard Medical School. He has contributed more than 60 original research publications, reviews and chapters. Dr. LaBaer is an associate editor of the Journal of Proteome Research, Analytical Biochemistry, and a member of the Scientific Advisory Boards for the Proteome Society, Promega Corporation, Lumera-Plexera Corporation, Barnett Institute, and a founding member of the Human Proteome Organization |
|
Print version record |
| Subject |
Nanotechnology.
|
|
Biotechnology.
|
|
Biotechnology
|
|
Nanotechnology
|
|
bioengineering.
|
|
MEDICAL -- Biotechnology.
|
|
MEDICAL -- Pharmacology.
|
|
SCIENCE -- Biotechnology.
|
|
Biotechnology
|
|
Nanotechnology
|
| Form |
Electronic book
|
| Author |
Nicolini, Claudio A.
|
| ISBN |
9789814267779 |
|
9814267775 |
|
9780429111594 |
|
0429111592 |
|
9780429548475 |
|
0429548478 |
|
9780429533778 |
|
0429533772 |
|
